What's Happening?
Paul Hastings LLP has announced the addition of Lisa DeMarchi Sleigh, a former Deputy Assistant Director in the Mergers I Division of the Federal Trade Commission (FTC), as a partner in its Antitrust & Competition practice in Washington, D.C. DeMarchi Sleigh's
role at the FTC involved analyzing proposed mergers and acquisitions and recommending enforcement actions, primarily within the life sciences and healthcare sectors. Her expertise covers branded and generic pharmaceuticals, medical devices, consumer products, and scientific and industrial products. This strategic hire is part of Paul Hastings' ongoing effort to strengthen its global Antitrust & Competition practice, which has nearly tripled in size over the past four years. The firm has also seen significant growth in its U.S. deal value, with Bloomberg reporting a 15-fold increase in total deal value from 2023 to 2025, reaching $272 billion. The firm's average deal value also climbed to $1.7 billion, nearly seven times its 2023 average.
Why It's Important?
The recruitment of a high-profile former FTC official like Lisa DeMarchi Sleigh is significant for Paul Hastings and its corporate clients, particularly those in the pharmaceutical and life sciences sectors. Her "insider perspective and advice" on managing regulatory risks and challenges for major transactions will be invaluable in an environment of increasing merger and acquisition (M&A) volume and deal size. This move reflects a broader trend in the legal industry where firms seek to enhance their regulatory expertise to navigate complex antitrust landscapes. For U.S. businesses, especially those involved in large-scale M&A, having access to attorneys with direct experience from regulatory bodies like the FTC can be crucial for successful deal execution and compliance. The firm's substantial growth in U.S. deal value, as reported by Bloomberg, further underscores the importance of robust antitrust counsel in facilitating significant corporate transactions and maintaining market competitiveness.
What's Next?
Paul Hastings anticipates further expansion of its antitrust talent, with additional professionals expected to join the firm. This continued growth suggests a strategic focus on bolstering its capabilities in response to the evolving regulatory environment and the increasing complexity of corporate transactions. The firm's emphasis on the pharmaceutical and life sciences sectors indicates a proactive approach to serving clients in industries experiencing high M&A activity. Clients of Paul Hastings can expect enhanced guidance on navigating antitrust reviews and managing regulatory challenges, potentially leading to more efficient and compliant execution of their corporate strategies. The firm's trajectory of significant deal value growth suggests it will continue to be a major player in the U.S. M&A market, with its strengthened antitrust practice playing a key role in supporting these transactions.
Beyond the Headlines
The addition of Lisa DeMarchi Sleigh to Paul Hastings highlights a broader dynamic in the legal and regulatory landscape: the revolving door between government agencies and private practice. This phenomenon allows law firms to leverage the specialized knowledge and experience of former regulators, offering clients a unique advantage in understanding and navigating complex legal frameworks. While beneficial for clients seeking expert guidance, it also raises questions about the potential for regulatory capture or the perception of unfair advantage. The move underscores the increasing importance of antitrust enforcement in the U.S. economy, particularly in sectors like healthcare and life sciences, where consolidation can have significant impacts on competition, innovation, and consumer welfare. As regulatory scrutiny intensifies, the demand for legal professionals with deep regulatory insight will likely continue to grow, shaping the strategies of both law firms and the corporations they advise.
